D-0105-2021 Class III Terminated
FDA drug recall D-0105-2021 was initiated by Fresenius Kabi USA, LLC on Nov 17, 2020 and is designated Class III. Reason for recall: Cross Contamination with Other Products: trace amounts of octreotide found during testing The recall status is terminated (terminated Aug 25, 2022). Affected quantity: 16,986 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Dec 2, 2020
- Initiation Date
- Nov 17, 2020
- Termination Date
- Aug 25, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 16,986 vials
Product description
DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047. NDC: 63323-883-05
Reason for recall
Cross Contamination with Other Products: trace amounts of octreotide found during testing
Distribution pattern
Nationwide USA and Puerto Rico
Code information
Batch: 6120525, exp 11/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0105-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026